Cytology and HPV Testing Market

Cytology and HPV Testing Market (Product and Services - Cytology Testing (Systems, Assay Kits, Services), HPV Testing - Systems, Assay Kits, Services) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2019 - 2027

  • According to Transparency Market Research’s latest report on the global cytology and HPV testing market for the historical period 2017–2018 and forecast period 2019–2027, high incidence rate of HPV infections and increasing incidence of cervical cancer worldwide are projected to drive the global cytology and HPV testing market during the forecast period
  • According to the report, the global cytology and HPV testing market was valued at US$ 7.42 Bn in 2018 and is anticipated to expand at a CAGR of 5.9% from 2019 to 2027

Rising Incidence of Cervical Cancer Worldwide: Key Drivers

  • According to the American Cancer Society, cervical cancer is one of the most common causes of cancer death for in women in the U.S. In addition, according to the organization, it has been estimated that approximately 12,990 women in the U.S. would be diagnosed with cervical cancer and 4,120 deaths would occur from this disease in 2016.
  • However, as per various research studies conducted by the Centers for Disease Control and Prevention, the number of new cases of cervical cancer patients and the number of deaths due to cervical cancer have decreased significantly in the past 40 years i.e., between 1955 and 1992, the cervical cancer death rate declined by almost 70% in U.S.
  • The decline in death rate is attributed to factors such as increased use of Pap screening test and growing awareness among cervical cancer patients about screening tests available commercially in the market and the offered benefits for disease prevention
  • Thus, considering all the factors mentioned above, increasing prevalence rate of cervical cancer patients, growing awareness about disease prevention, and large-scale availability of screening kits and diagnostic products are expected to increase the adoption of diagnostic tests, thereby boosting the growth of the market
  • Thus, increasing incidence of cervical cancer is likely to boost the cytology and HPV testing market during the forecast period

High Incidence Rate of HPV Infection to Boost Market Growth

  • HPV infection is one of the most common causes of cervical cancer. It accounts for about 90% of cervical cancer cases and is diagnosed through Pap smear screening and HPV testing.
  • The spread of HPV infection poses a great threat to an individual’s immune system and leads to the conversion of normal cervix cells into cancerous cells. Two types of HPV infections — HPV 16 and HPV 18 — account for 70% of the overall cervical cancer cases and are termed as “high-risk” infections.
  • According to the World Health Organization (WHO), cervical cancer is the most prevalent HPV-related disease, with an estimated 530,000 new cases every year. Furthermore, according to the Cancer Research UK, about 3,100 women are diagnosed with cervical cancer each year in the country.
  • Various factors contributing to the high incidence rate of HPV infections include weakened immune system, smoking, chronic inflammation and long-term oral contraceptive use. The International Agency for Research and Cancer predicted that the rate of HPV related cervical cancer would rise by 40% in the near future.
  • Hence, HPV infection remains one of the leading causes of cervical cancer and rising prevalence and incidence rates are expected to drive the growth of the market

Lack of Appropriate Primary Healthcare Infrastructure to Hamper Market

  • Lack of proper healthcare infrastructure and the presence of outdated facilities in most of the developing countries and emerging markets are the biggest restraints of the cytology and HPV testing market
  • It has been observed that a large number of patients in many developing regions do not have access to modern primary healthcare infrastructure such as labs, clinics, diagnostic centers, equipment and supplies, and trained laboratory experts. Hence, inadequate and unreliable infrastructure deters the patient population from HPV and cytology testing.
  • Due to lack of primary care infrastructure for testing and diagnostics in various emerging countries such as Brazil, China and India, patients are constantly seeking treatment from hospitals, thereby raising the hospitalization cost rates. Consequently, most of the patients evade screening tests to avoid high hospitalization costs.
  • According to the Organization for Economic Co-operation and Development (OECD), Mexico spends 6.2% of its GDP on healthcare, which is lower than the average of 9.5% in OECD countries. This has resulted in lack of resources allocated for the country’s healthcare infrastructure leading to inappropriate medical care units such as operating rooms and insufficient beds.
  •  Therefore, insufficiency and poor distribution of resources for constructing medical infrastructure is expected to impede the growth of the cytology and HPV testing market

Global Cytology and HPV Testing Market: Competitive Landscape

  • This report profiles major players in the global cytology and HPV testing market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • Leading players operating in the global cytology and HPV testing market are
    • Becton
    • Dickinson and Company
    • Cepheid, Inc.
    • Abbott Laboratories, Inc.
    • F. Hoffmann-La Roche AG
    • Fujirebio Diagnostics, Inc.
    • Arbor Vita Corporation
    • Hologic, Inc.
    • QIAGEN N.V.
    • OncoHealth Corporation

Global Cytology and HPV Testing Market: Key Developments

Key players in the global cytology and HPV Testing market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global cytology and HPV Testing market. A few expansion strategies adopted by players operating in the global cytology and HPV Testing market are:

  • In September 2015, Becton, Dickinson and Company (BD) launched the BD FACSCelesta, an advanced technique for BD cell analyzer portfolio, at the American Society for Cell Biology annual meeting. The coverage of cytometer facilitates high resolution cell population and measures 14 diverse single cell characteristics which is a perfect solution for researchers
  • In February 2015, the company acquired Signature Diagnostics, a genomics and translational oncology company. The acquisition would strengthen Roche’s next generation sequencing (NGS) diagnostics business. Roche will leverage Signature’s unique expertise in both biobanks and NGS assays to develop novel diagnostics for cancer patients.
  • In February 2014, Health Canada approved the use of Aptima HPV 16 18/45 Genotype Assay on Hologic's Panther System. This completed the HPV portfolio on the popular and fully automated laboratory system.

The report on the global cytology and HPV Testing market discussed individual strategies, followed by company profiles of manufacturers of cytology and HPV Testing. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global cytology and HPV Testing market.

Global Cytology and HPV Testing Market - Segmentation

Product Type

HPV Testing

Cytology Testing

Product Sub-types

Assay Kits

Systems

Services

Region

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Frequently Asked Questions

What is the total market worth of cytology and HPV testing market?

Cytology and HPV testing market to reach US$ 12.54 Bn by 2027

What is the anticipated CAGR of the cytology and HPV testing market in the forecast period?

Cytology and HPV testing market is anticipated to expand at a CAGR of 5.9% from 2019 to 2027

What are the key driving factors for the growth of the cytology and HPV testing market?

Cytology and HPV testing market is driven by increasing incidence of HPV infections and cervical cancer and weakening immune system of the population

Which region is expected to project the highest market share in the global cytology and HPV testing market?

North America accounted for a major share of the global cytology and HPV testing market

Who are the key players in the global cytology and HPV testing market?

Key players in the global cytology and HPV testing market Becton, Dickinson and Company, Cepheid, Inc., Abbott Laboratories, Inc., F. Hoffmann-La Roche AG, Fujirebio Diagnostics, Inc.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Cytology and HPV Testing Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Market Introduction

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Cytology and HPV Testing Market Analysis and Forecasts, 2017–2027

            4.4.1. Market Revenue Projections (US$ Mn)

        4.5. Porter’s Five Force Analysis

    5. Market Outlook

        5.1. Key Mergers & Acquisitions 

        5.2. Technological Advancements

    6. Global Cytology and HPV Testing Market Analysis and Forecasts, by Product Type 

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast by Product, 2017–2027

            6.3.1. HPV Testing

                6.3.1.1. Assay Kits

                6.3.1.2. Systems

                6.3.1.3. Services

            6.3.2. Cytology Testing

                6.3.2.1. Assay Kits

                6.3.2.2. Systems

                6.3.2.3. Services

        6.4. Market Attractiveness by Product  

    7. Global Cytology and HPV Testing Market Analysis and Forecasts, by Region

        7.1. Key Findings

        7.2. Market Value Forecast by Region

            7.2.1. North America 

            7.2.2. Europe 

            7.2.3. Asia Pacific 

            7.2.4. Latin America 

            7.2.5. Middle East & Africa 

        7.3. Market Attractiveness by Country/Region

    8. North America Cytology and HPV Testing Market Analysis and Forecast

        8.1. Introduction

            8.1.1. Key Findings

        8.2. Market Value Forecast by Product, 2017–2027

            8.2.1. HPV Testing

                8.2.1.1. Assay Kits

                8.2.1.2. Systems

                8.2.1.3. Services

            8.2.2. Cytology Testing

                8.2.2.1. Assay Kits

                8.2.2.2. Systems

                8.2.2.3. Services

        8.3. Market Value Forecast by Country, 2017–2027

            8.3.1. U.S.

            8.3.2. Canada

        8.4. Market Attractiveness Analysis 

            8.4.1. By Product Type 

            8.4.2. By Country

    9. Europe Cytology and HPV Testing Market Analysis and Forecast

        9.1. Introduction

            9.1.1. Key Findings

        9.2. Market Value Forecast by Product, 2017–2027

            9.2.1. HPV Testing

                9.2.1.1. Assay Kits

                9.2.1.2. Systems

                9.2.1.3. Services

            9.2.2. Cytology Testing

                9.2.2.1. Assay Kits

                9.2.2.2. Systems

                9.2.2.3. Services

        9.3. Market Value Forecast by Country/Sub-region, 2017–2027

            9.3.1. Germany

            9.3.2. U.K.

            9.3.3. France

            9.3.4. Italy

            9.3.5. Spain

            9.3.6. Rest of Europe

        9.4. Market Attractiveness Analysis 

            9.4.1. By Product Type 

            9.4.2.  By Country/Sub-region

    10. Asia Pacific Cytology and HPV Testing Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast by Product, 2017–2027

            10.2.1. HPV Testing

                10.2.1.1. Assay Kits

                10.2.1.2. Systems

                10.2.1.3. Services

            10.2.2. Cytology Testing

                10.2.2.1. Assay Kits

                10.2.2.2. Systems

                10.2.2.3. Services

        10.3. Market Value Forecast by Country/Sub-region, 2017–2027

            10.3.1. China

            10.3.2. India

            10.3.3. Japan

            10.3.4. Australia & New Zealand

            10.3.5. Rest of Asia Pacific

        10.4. Market Attractiveness Analysis 

            10.4.1. By Product Type 

            10.4.2. By Country/Sub-region

    11. Latin America Cytology and HPV Testing Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast by Product, 2017–2027

            11.2.1. HPV Testing

                11.2.1.1. Assay Kits

                11.2.1.2. Systems

                11.2.1.3. Services

            11.2.2. Cytology Testing

                11.2.2.1. Assay Kits

                11.2.2.2. Systems

                11.2.2.3. Services

        11.3. Market Value Forecast by Country/Sub-region, 2017–2027

            11.3.1. Brazil

            11.3.2. Mexico

            11.3.3. Rest of Latin America

        11.4. Market Attractiveness Analysis 

            11.4.1. By Product Type 

            11.4.2. By Country/Sub-region

    12. Middle East & Africa Cytology and HPV Testing Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast by Product, 2017–2027

            12.2.1. HPV Testing

                12.2.1.1. Assay Kits

                12.2.1.2. Systems

                12.2.1.3. Services

            12.2.2. Cytology Testing

                12.2.2.1. Assay Kits

                12.2.2.2. Systems

                12.2.2.3. Services

        12.3. Market Value Forecast by Country/Sub-region, 2017–2027

            12.3.1. GCC Countries

            12.3.2. South Africa

            12.3.3. Rest of Middle East & Africa

        12.4. Market Attractiveness Analysis 

            12.4.1. By Product 

            12.4.2. By Country/Sub-region

    13. Competition Landscape

        13.1. Market Player – Competition Matrix (by Tier and Size of companies)

        13.2. Market Share Analysis by Company (2018)

        13.3. Company Profiles

            13.3.1. Becton, Dickinson and Company

                13.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.1.2. Growth Strategies

                13.3.1.3. SWOT Analysis

            13.3.2. Cepheid, Inc.

                13.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.2.2. Growth Strategies

                13.3.2.3. SWOT Analysis

            13.3.3. Abbott Laboratories, Inc.

                13.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.3.2. Growth Strategies

                13.3.3.3. SWOT Analysis

            13.3.4. F. Hoffmann-La Roche AG

                13.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.4.2. Growth Strategies

                13.3.4.3. SWOT Analysis

            13.3.5. Fujirebio Diagnostics, Inc.

                13.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.5.2. Growth Strategies

                13.3.5.3. SWOT Analysis

            13.3.6. Arbor Vita Corporation

                13.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.6.2. Growth Strategies

                13.3.6.3. SWOT Analysis

            13.3.7. Hologic, Inc.

                13.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.7.2. Growth Strategies

                13.3.7.3. SWOT Analysis

            13.3.8. QIAGEN N.V.

                13.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.8.2. Growth Strategies

                13.3.8.3. SWOT Analysis

            13.3.9. OncoHealth Corporation

                13.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                13.3.9.2. Growth Strategies

                13.3.9.3. SWOT Analysis

    List of Tables

    TABLE 01: Global Cytology and HPV Testing Market Size (US$ Mn) Forecast, By Product, 2017–2027

    TABLE 02: Global Cytology and HPV Testing Market Size (US$ Mn) Forecast, By HPV Testing Type, 2017–2027

    TABLE 03: Global Cytology and HPV Testing Market Size (US$ Mn) Forecast, By Cytology Testing Type, 2017–2027

    TABLE 04: Global Cytology and HPV Testing Market Size (US$ Mn) Forecast, By Region, 2017–2027

    TABLE 05: North America Cytology and HPV Testing Market Size (US$ Mn) Forecast, By Product, 2017–2027

    TABLE 06: North America Cytology and HPV Testing Market Size (US$ Mn) Forecast, By HPV Testing, 2017–2027

    TABLE 07: North America Cytology and HPV Testing Market Size (US$ Mn) Forecast, By Cytology Testing, 2017–2027

    TABLE 08: North America Cytology and HPV Testing Market Size (US$ Mn) Forecast, By Country, 2017–2027

    TABLE 09: Europe Cytology and HPV Testing Market Size (US$ Mn) Forecast, By Product, 2017–2027

    TABLE 10: Europe Cytology and HPV Testing Market Size (US$ Mn) Forecast, By HPV Testing, 2017–2027

    TABLE 11: Europe Cytology and HPV Testing Market Size (US$ Mn) Forecast, By Cytology Testing, 2017–2027

    TABLE 12: Europe Cytology and HPV Testing Market Size (US$ Mn) Forecast, By Country, 2017–2027

    TABLE 13: Latin America Cytology and HPV Testing Market Size (US$ Mn) Forecast, By Product, 2017–2027

    TABLE 14: Latin America Cytology and HPV Testing Market Size (US$ Mn) Forecast, By HPV Testing Type, 2017–2027

    TABLE 15: Latin America Cytology and HPV Testing Market Size (US$ Mn) Forecast By Cytology Testing, 2017–2027

    TABLE 16: Latin America Cytology and HPV Testing Market Size (US$ Mn) Forecast, By Country, 2017–2027

    TABLE 17: APAC Cytology and HPV Testing Market Size (US$ Mn) Forecast, By Product, 2017–2027

    TABLE 18: APAC Cytology and HPV Testing Markets Size (US$ Mn) Forecast, by HPV Testing, 2017–2027

    TABLE 19: APAC Cytology and HPV Testing Market Size (US$ Mn) Forecast, by Cytology Testing, 2017–2027

    TABLE 20: APAC Cytology and HPV Testing Market Size (US$ Mn) Forecast, By Country, 2017–2027

    TABLE 21: MEA Cytology and HPV Testing Market Size (US$ Mn) Forecast, By Product, 2017–2027

    TABLE 22: MEA Cytology and HPV Testing Market Size (US$ Mn) Forecast, By HPV Testing, 2017–2027

    TABLE 23: MEA Cytology and HPV Testing Market Size (US$ Mn) Forecast, By Cytology Testing, 2017–2027

    TABLE 24: MEA Cytology and HPV Testing Market Size (US$ Mn) Forecast, By Country, 2017–2027

    List of Figures

    FIGURE 1 Global Cytology and HPV Testing Market Value Share Analysis, 2019 and 2027

    FIGURE 2 Global Cytology and HPV Testing Market Value Share Analysis By Product, 2019 and 2027

    FIGURE 3 Global Cytology and HPV Testing Market Value Share Analysis By HPV Testing, 2019 and 2027

    FIGURE 4 Global Cytology and HPV Testing Market Value Share Analysis By Cytology Testing, 2019 and 2027

    FIGURE 5 Global Cytology and HPV Testing Market Revenue (US$ Mn) and Y-o-Y growth (%), By Product, 2018–2027

    FIGURE 6 Global Cytology and HPV Testing Market Revenue (US$ Mn) and Y-o-Y growth (%), By HPV Testing, 2018–2027

    FIGURE 7 Global Cytology and HPV Testing Market Revenue (US$ Mn) and Y-o-Y growth (%), By Cytology Testing, 2018–2027

    FIGURE 8 Global Cytology and HPV Testing Market Revenue (US$ Mn) and Y-o-Y growth (%), By Region, 2018–2027

    FIGURE 9 Global Cytology and HPV Testing Market Attractiveness Analysis, by Product 

    FIGURE 10 Global Cytology and HPV Testing Market Value Share Analysis By Region, 2019 and 2027

    FIGURE 11 Global Cytology and HPV Testing Market Attractiveness Analysis, by Region

    FIGURE 12 North America Cytology and HPV Testing Market Size (US$ Mn) Forecast, 2017–2027

    FIGURE 13 North America Cytology and HPV Testing Market Revenue (US$ Mn) and Y-o-Y growth (%), By Product, 2018–2027

    FIGURE 14 North America Cytology and HPV Testing Market Attractiveness Analysis, by Country

    FIGURE 15 North America Market Value Share Analysis By Product, 2019 and 2027

    FIGURE 16 North America Market Value Share Analysis By HPV Testing, 2019 and 2027

    FIGURE 17 North America Market Value Share Analysis By Cytology Testing, 2019 and 2027

    FIGURE 18 North America Market Value Share Analysis By Country, 2019 and 2027

    FIGURE 19 North America Market Attractiveness Analysis, by Product 

    FIGURE 20 Europe Cytology and HPV Testing Market Size (US$ Mn) Forecast, 2017–2027

    FIGURE 21 Europe Cytology and HPV Testing Market Revenue (US$ Mn) and Y-o-Y growth (%), By Product, 2018–2027

    FIGURE 22 Europe Cytology and HPV Testing Market Attractiveness Analysis, by Country

    FIGURE 23 Europe Market Value Share Analysis By Product, 2019 and 2027

    FIGURE 24 Europe Market Value Share Analysis By HPV Testing, 2019 and 2027

    FIGURE 25 Europe Market Value Share Analysis By Cytology Testing, 2019 and 2027

    FIGURE 26 Europe Market Value Share Analysis By Country, 2019 and 2027

    FIGURE 27 Europe Market Attractiveness Analysis, by Product

    FIGURE 28 Latin America Cytology and HPV Testing Market Size (US$ Mn) Forecast, 2017–2027

    FIGURE 29 Latin America Cytology and HPV Testing Market Revenue (US$ Mn) and Y-o-Y growth (%), By Product, 2018–2027

    FIGURE 30 Latin America Cytology and HPV Testing Market Attractiveness Analysis, by Country

    FIGURE 31 Latin America Market Value Share Analysis By Product, 2019 and 2027

    FIGURE 32 Latin America Market Value Share Analysis By HPV Testing, 2019 and 2027

    FIGURE 33 Latin America Market Value Share Analysis By Cytology Testing, 2019 and 2027

    FIGURE 34 Latin America Market Value Share Analysis By Country, 2019 and 2027

    FIGURE 35 Latin America Market Attractiveness Analysis, by Product

    FIGURE 36 APAC Cytology and HPV Testing Market Size (US$ Mn) Forecast, 2017–2027

    FIGURE 37 APAC Cytology and HPV Testing Market Revenue (US$ Mn) and Y-o-Y growth (%), By Product, 2018–2027

    FIGURE 38 APAC Cytology and HPV Testing Market Attractiveness Analysis, by Country

    FIGURE 39 APAC Market Value Share Analysis By Product, 2019 and 2027

    FIGURE 40 APAC Market Value Share Analysis By HPV Testing, 2019 and 2027

    FIGURE 41 APAC Market Value Share Analysis By Cytology Testing, 2019 and 2027

    FIGURE 42 APAC Market Value Share Analysis By Country, 2019 and 2027

    FIGURE 43 APAC Market Attractiveness Analysis, by Product

    FIGURE 44 MEA Cytology and HPV Testing Market Size (US$ Mn) Forecast, 2017–2027

    FIGURE 45 MEA Cytology and HPV Testing Market Revenue (US$ Mn) and Y-o-Y growth (%), By Product, 2018–2027

    FIGURE 46 MEA Cytology and HPV Testing Market Attractiveness Analysis, by Country

    FIGURE 47 MEA Market Value Share Analysis By Product, 2019 and 2027

    FIGURE 48 MEA Market Value Share Analysis By HPV Testing, 2019 and 2027

    FIGURE 49 MEA Market Value Share Analysis By Cytology Testing, 2019 and 2027

    FIGURE 50 MEA Market Value Share Analysis By Country, 2019 and 2027

    FIGURE 51 MEA Market Attractiveness Analysis, by Product

    FIGURE 52 Global Cytology and HPV Testing Market Share Analysis By Company (2018)

    FIGURE 53 Becton, Dickinson and Company Breakdown of Net Sales, by Region, 2018

    FIGURE 54 Becton, Dickinson and Company Breakdown of Net Sales, by Segment, 2018

    FIGURE 55 Becton, Dickinson and Company Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2018

    FIGURE 56 Cepheid, Inc. Breakdown of Net Sales, by Region, 2018

    FIGURE 57 Cepheid, Inc. Breakdown of Net Sales, by Segment, 2018

    FIGURE 58 Cepheid, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2018

    FIGURE 59 Abbott Laboratories, Inc. Breakdown of Net Sales, by Region, 2018

    FIGURE 60 Abbott Laboratories, Inc. Breakdown of Net Sales, by Segment, 2018

    FIGURE 61 Abbott Laboratories, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2018

    FIGURE 62 F. Hoffmann-La Roche AG Breakdown of Net Sales, by Region, 2018

    FIGURE 63 F. Hoffmann-La Roche AG Breakdown of Net Sales, by Segment, 2018

    FIGURE 64 F. Hoffmann-La Roche AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2018

    FIGURE 65 Fujirebio Diagnostics, Inc. Breakdown of Net Sales, by Region, 2018

    FIGURE 66 Fujirebio Diagnostics, Inc. Breakdown of Net Sales, by Segment, 2018

    FIGURE 67 Fujirebio Diagnostics, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2018

    FIGURE 68 Arbor Vita Corporation Breakdown of Net Sales, by Region, 2018

    FIGURE 69 Arbor Vita Corporation Breakdown of Net Sales, by Segment, 2018

    FIGURE 70 Arbor Vita Corporation Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2018

    FIGURE 71 Hologic, Inc. Breakdown of Net Sales, by Region, 2018

    FIGURE 72 Hologic, Inc. Breakdown of Net Sales, by Segment, 2018

    FIGURE 73 Hologic, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2018

    FIGURE 74 QIAGEN N.V. Breakdown of Net Sales, by Region, 2018

    FIGURE 75 QIAGEN N.V. Breakdown of Net Sales, by Segment, 2018

    FIGURE 76 QIAGEN N.V. Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2018

    FIGURE 77 OncoHealth Corporation Breakdown of Net Sales, by Region, 2018

    FIGURE 78 OncoHealth Corporation Breakdown of Net Sales, by Segment, 2018

    FIGURE 79 OncoHealth Corporation Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2018

Copyright © Transparency Market Research, Inc. All Rights reserved